Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* COVID-19 positive patients~* Treated at the Health Institute of the State of Mexico (ISEM).~* With risk factors to get complicated: age more than 60 years old, diabetes mellitus or obesity grade II or more.~Exclusion Criteria:~* Patients who have inherent contraindications to each drug.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nitazoxanide + hydroxychloroquine (Type: EXPERIMENTAL): Hydroxychloroquine 400 mg PO every 12 hours for two days and then 200 mg PO every 12 hours for four days + Nitazoxanide 500 mg PO every 6 hours for six days
- Hydroxychloroquine (Type: ACTIVE_COMPARATOR): Hydroxychloroquine 200 mg PO every 12 hours for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).